Datopotamab Deruxtecan

Antibody–drug conjugate

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, HR+/HER2- Metastatic Breast Cancer, Breast Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Urothelial Carcinoma · Phase 3

Also approved (6)
US
  • Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) DATROWAY is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the c
  • Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC) DATROWAY is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy [see Clinical Studies (14.2) ].
  • Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer DATROWAY is indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
Product first approved 2025FDA label
EU
  • Datroway monotherapy: 1st-line treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapyastrazeneca.com
  • Breast cancer Datroway as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting.
    EMA
Product first approved 2025
JP
  • Treatment of hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative unresectable or recurrent breast cancer in patients who have previously been treated with chemotherapy
Product first approved 2024PMDA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (16)
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
NCT07205822 · AstraZeneca
2025-10-30 – 2028-02-02 · Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT05215340 · Daiichi Sankyo
2022-03-04 – 2032-03-04 · Metastatic Non Small Cell Lung Cancer
What this study did
NCT06350097 · AstraZeneca
2024-04-29 – 2031-08-29 · Non-small Cell Lung Cancer
What this study did
NCT05555732 · Daiichi Sankyo
2023-01-11 – 2031-05-11 · Metastatic Non Small Cell Lung Cancer
What this study did
NCT07291037 · AstraZeneca
2025-10-31 – 2029-01-29 · Non-small Cell Lung Cancer (NSCLC)
What this study did
Urothelial Carcinoma
Phase 2/3 (1)
Urothelial Carcinoma
Phase 2 (17)
Breast Cancer
NCT07069595 · UNC Lineberger Comprehensive Cancer Center
2026-02-26 – 2032-11-01 · Breast Cancer, Residual Disease, Triple Negative Breast Cancer (TNBC), Stage II/III
What this study did
NCT01042379 · QuantumLeap Healthcare Collaborative
2010-03-01 – 2031-12 · Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT05866432 · Medical University of Vienna
2023-07-01 – 2027-07-01 · Breast Cancer Stage IV
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06533826 · Ana C Garrido-Castro, MD
2024-10-29 – 2038-08-01 · Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT07825753 · Fudan University
2026-09-10 – 2030-02-01 · Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC)
What this study did
NCT06974604 · Brown University
2025-10-22 – 2029-05-31 · Breast Neoplasms, Lung Neoplasms
What this study did
NCT07471776 · Fudan University
2026-03-11 – 2029-03-11 · Metastatic Breast Cancer ( HER2 Negative)
What this study did
NCT06176261 · Nancy Lin, MD
2024-01-08 – 2029-01-01 · Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma, ER Positive Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER-negative Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT05061550 · AstraZeneca
2022-04-14 – 2030-05-28 · Non-small Cell Lung Cancer
What this study did
NCT07098338 · AstraZeneca
2025-08-07 – 2029-04-06 · Non-Small Cell Lung Cancer
What this study did
NCT07941609 · AstraZeneca
2026-11-30 – 2028-12-22 · Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT06822543 · Latin American Cooperative Oncology Group
2025-09-12 – 2028-11-01 · Lung Cancer, Non Small Cell Lung Cancer, Brain Metastases
What this study did
NCT04940325 · Gustave Roussy, Cancer Campus, Grand Paris
2021-05-12 – 2028-09 · Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer, Unresectable Non-small Lung Cancer
What this study did
NCT06676917 · MedSIR
2025-06 – 2027-08 · Non-small Cell Lung Cancer
What this study did
NCT03944772 · AstraZeneca
2019-06-25 – 2025-05-06 · Non-Small Cell Lung Cancer
What this study did
Urothelial Carcinoma
NCT05489211 · AstraZeneca
2022-09-06 – 2027-10-01 · Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer
What this study did
Phase 1/2 (9)
Breast Cancer
NCT06508216 · Gustave Roussy, Cancer Campus, Grand Paris
2024-07-05 – 2027-12-17 · Breast Cancer
What this study did
NCT03742102 · AstraZeneca
2018-12-21 – 2027-02-26 · Triple Negative Breast Neoplasms
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07738341 · Eddingpharm (Zhuhai) Co., Ltd.
2026-07-28 – 2030-08-01 · Breast Cancer (Locally Advanced or Metastatic)
What this study did
NCT04644068 · AstraZeneca
2020-11-12 – 2027-05-28 · Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5
What this study did
Non-Small Cell Lung Cancer
NCT07890714 · Daiichi Sankyo
2026-10-16 – 2030-01-31 · Urothelial Cancer, Non-small Cell Lung Cancer
What this study did
NCT07535437 · Memorial Sloan Kettering Cancer Center
2026-04-09 – 2028-04 · Non-Small Cell Lung Cancer
What this study did
NCT05460273 · AstraZeneca
2022-07-11 – 2027-06-30 · Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Cancer
What this study did
Other / comorbidity
NCT06130553 · AstraZeneca
2024-01-18 – 2028-12-04 · Advanced Solid Tumors That Are MTAP Deficient
What this study did
NCT05417594 · AstraZeneca
2022-06-24 – 2028-02-07 · Advanced Solid Malignancies
What this study did
Phase 1 (5)
HR+/HER2- Metastatic Breast Cancer
NCT03401385 · Daiichi Sankyo Co., Ltd.
2018-01-31 – 2028-01-01 · Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer
What this study did
Non-Small Cell Lung Cancer
NCT04612751 · AstraZeneca
2021-02-02 – 2027-05-04 · Advanced or Metastatic NSCLC
What this study did
NCT04526691 · Daiichi Sankyo
2020-09-15 – 2026-12-31 · Advanced or Metastatic NSCLC
What this study did
NCT05117476 · Cullinan Therapeutics Inc.
2021-10-29 – 2026-06 · Advanced Solid Tumor, NSCLC
What this study did
Other / comorbidity
NCT06244485 · Daiichi Sankyo
2024-02-22 – 2028-11-01 · Advanced Solid Tumor
What this study did
Phase 4 (1)
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Breast Cancer
NCT06954480 · Queen Mary University of London
2025-10-27 – 2030-02 · Triple Negative Breast Cancer
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Breast Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Datopotamab Deruxtecan: this drugApprovedAntibody–drug conjugateTROP2Partial signal
NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5)
Abemaciclib (Verzenio)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4)
NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5)
Alpelisib (BYL719)ApprovedSmall moleculePI3K-alphaReliable signal
NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36)
Camizestrant (Etcamah)ApprovedSmall moleculeEstrogen receptorReliable signal
NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001
NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81)
CapivasertibApprovedSmall moleculeAKT (inhibitor)Reliable signal
NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7)
NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed
ElacestrantApprovedSmall moleculeEstrogen receptorPartial signal
NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14)
EpirubicinApprovedSmall moleculeTopoisomerase II / DNAPartial signal
NCT00309569: Overall survival (primary endpoint), preoperative vs postoperative chemo timing: HR 0.800 (95% CI 0.563-1.136), P=0.213 — no significant difference. (Secondary endpoint recurrence-free survival: HR 0.7, 95% CI 0.515-0.955, P=0.024, favoring postoperative chemo.) missed
Eribulin MesylateApprovedSmall moleculeTubulin / microtubulesPartial signal
NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms
NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Partial signal
NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164)
NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14)
ExemestaneApprovedSmall moleculeAromataseReliable signal
NCT00038467: Disease-Free Survival (DFS) at Month 36 Post-Randomization: Main Study (Baseline up to Month 36): Exemestane 0.9 probability of DFS (95% CI 0.89 to 0.92) vs Tamoxifen 0.86 probability of DFS (95% CI 0.85 to 0.88)
NCT00066690: 5-year disease-free survival: 89.0% exemestane plus ovarian function suppression vs 84.7% tamoxifen alone; HR 0.68 (95% CI 0.53–0.86).
Fulvestrant (Faslodex)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59)
NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010).
Gedatolisib (Revtorpyk)ApprovedSmall moleculePI3K (class I isoforms) and mTORC1/mTORC2Partial signal
NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001.
Imlunestrant (Inluriyo)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001
Inavolisib (Itovebi)ApprovedSmall moleculePI3K-alphaReliable signal
NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3)
IxabepiloneApprovedSmall moleculeMicrotubules (tubulin)Partial signalFeatured results are non-efficacy only in this race
Margetuximab (Margenza)ApprovedMonoclonal antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed
NeratinibApprovedSmall moleculeEGFR/HER2Reliable signal
NCT00878709: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 (From randomization until time of event up to 2 years): Neratinib 4.7 percentage of participants with events vs Placebo 7.5 percentage of participants with events
NCT01808573: Centrally Assessed Progression Free Survival (From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut.): Neratinib Plus Capecitabine 8.8 months (95% CI 7.8 to 9.8) vs Lapatinib Plus Capecitabine 6.6 months (95% CI 5.9 to 7.4)
OlaparibApprovedSmall moleculePARPPartial signal
NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3)
NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17)
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6)
NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PertuzumabApprovedMonoclonal antibodyHER2/neu Receptor AntagonistPartial signal
NCT01358877: IDFS events, pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy: 7.1% vs 8.7%, hazard ratio 0.81 (95% CI 0.66 to 1.00), p=0.0446 (log-rank); 3-year IDFS event-free rate 94.06% vs 93.24% (CT.gov posted results, data cut-off 19 December 2016).
NCT00567190: IRF-assessed progression-free survival, pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel: median 18.5 vs 12.4 months, hazard ratio 0.62 (95% CI 0.51 to 0.75), p<0.0001 (stratified log-rank; CT.gov posted results).
RibociclibApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3)
NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4)
Sacituzumab GovitecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4)
NCT02574455: Progression-Free Survival (PFS) by Independent Review Committee (IRC) Assessment in Brain Metastasis Negative (BM-ve) Population (From randomization until objective tumor progression or death (assessed every 6 weeks for 9 months and then every 9 weeks thereafter until the occurrence of progression of disease; maximum exposure: 29.6 months)): Sacituzumab Govitecan 5.6 months (95% CI 4.3 to 6.3) vs Treatment of Physician's Choice (TPC) 1.7 months (95% CI 1.5 to 2.6)
TalazoparibApprovedSmall moleculePARPPartial signal
NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7)
Tamoxifen (Soltamox)ApprovedSmall moleculeEstrogen receptornot yet graded
NCT00066690: Disease-free Survival (5-year estimates, reported at a median follow-up of 67 months.): T+OFS 86.6% (95% CI 84.2 to 88.7) | E+OFS 89% (95% CI 86.8 to 90.9) vs Tamoxifen 84.7% (95% CI 82.2 to 86.9) phase 3 result · pivotal pending
NCT00309478: At median 60-month follow-up: relapse rate 17.2% (goserelin+tamoxifen) vs 20.8% (CMF), relapse-free survival difference P=.037; local recurrence 4.7% vs 8.0%, P=.015; overall survival difference only a trend, P=.195. phase 3 result · pivotal pending
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1)
Trastuzumab EmtansineApprovedAntibody–drug conjugateHER2 (ERBB2)Partial signalFeatured results are non-efficacy only in this race
TucatinibApprovedSmall moleculeHER2Reliable signal
NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001.
NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1)
Vepdegestrant (Veppanu)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025).
NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41)
BEBT-209Phase 3Small moleculeCDK4 (selective)not yet gradedNo reviewed efficacy summary in this indication
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signalNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05347134: OptiTROP-Breast01 (NCT05347134), primary endpoint median PFS: sac-TMT 6.7 months vs chemotherapy 2.5 months; HR 0.32 (95% CI 0.24-0.44); p<0.00001
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
(Z)-EndoxifenPhase 2Small moleculeEstrogen receptor (antagonist)Partial signal
NCT03931928: Primary endpoint (proportion of patients with steady-state (Z)-endoxifen plasma concentration >32 nmol/L after 6 weeks): higher proportion achieved target in both (Z)-endoxifen supplementation arms (3mg and 1.5mg) than in the control/placebo arm, P<0.0001.
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
TersolisibPhase 2Small moleculePI3K-alpha (mutant-selective, allosteric)not yet gradedNo reviewed efficacy summary in this indication
ECI830Phase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
GVV858Phase 1/2—CDK2not yet gradedNo reviewed efficacy summary in this indication
HRS-2189Phase 1/2UndisclosedKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
HRS-6208Phase 1/2UndisclosedCDK7not yet gradedNo reviewed efficacy summary in this indication
TegtociclibPhase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
IEV407Phase 1——not yet gradedNo reviewed efficacy summary in this indication
JNJ-101684362Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
RAE346
—(overall)
Small moleculePI3Kα (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(35 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Datopotamab Deruxtecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (8)
January 2027 (1)
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-01-11 · NCT06417814 · CT.gov ↗
What to watch
May 2027 (2)
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-05-28 · NCT04644068 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-05-31 · NCT06974604 · CT.gov ↗
What to watch
July 2027 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2027-07-28 · NCT06103864 · CT.gov ↗
What to watch
September 2027 (2)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-09-01 · NCT07825753 · CT.gov ↗
What to watch
Phase 3Breast CancerActive not recruiting
Est. primary completion 2027-09-01 · NCT05629585 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2027-10-01 · NCT05489211 · CT.gov ↗
What to watch
November 2027 (1)
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-11-01 · NCT05687266 · CT.gov ↗
What to watch
2028 (15)
January 2028 (4)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-01-01 · NCT03401385 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-01-01 · NCT06176261 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-01-01 · NCT06533826 · CT.gov ↗
What to watch
Phase 4Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-01-04 · NCT07357597 · CT.gov ↗
What to watch
February 2028 (2)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-02-02 · NCT07205822 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid MalignanciesRecruiting
Est. primary completion 2028-02-07 · NCT05417594 · CT.gov ↗
What to watch
March 2028 (2)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-03-11 · NCT07471776 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-03-21 · NCT06350097 · CT.gov ↗
What to watch
April 2028 (2)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-04 · NCT07535437 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-04 · NCT04940325 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-30 · NCT06822543 · CT.gov ↗
What to watch
November 2028 (2)
Phase 1Advanced Solid TumorActive not recruiting
Est. primary completion 2028-11-01 · NCT06244485 · CT.gov ↗
What to watch
Phase 3Breast CancerActive not recruiting
Est. primary completion 2028-11-20 · NCT06112379 · CT.gov ↗
What to watch
December 2028 (2)
Phase 1/2Advanced Solid Tumors That Are MTAP DeficientRecruiting
Est. primary completion 2028-12-04 · NCT06130553 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12-16 · NCT07941609 · CT.gov ↗
What to watch
2029 (7)
January 2029 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-01-29 · NCT07291037 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-04-06 · NCT07098338 · CT.gov ↗
What to watch
May 2029 (1)
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-05-11 · NCT05555732 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2/3Urothelial CarcinomaRecruiting
Est. primary completion 2029-06-01 · NCT07129993 · CT.gov ↗
What to watch
August 2029 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-08-01 · NCT07738341 · CT.gov ↗
What to watch
September 2029 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-09-30 · NCT07890714 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-12-28 · NCT06357533 · CT.gov ↗
What to watch
2030 (4)
March 2030 (1)
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-03-04 · NCT05215340 · CT.gov ↗
What to watch
May 2030 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-05-28 · NCT05061550 · CT.gov ↗
What to watch
September 2030 (1)
Phase 3Urothelial CarcinomaRecruiting
Est. primary completion 2030-09-11 · NCT07720284 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch
2031 (1)
November 2031 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2031-11-01 · NCT07069595 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

31 July 2026ApprovalDatroway approved in the EU for first-line metastatic TNBC in patients who are not candidates for immunotherapy
EU, EC/EMA · Source ↗
24 December 2024WithdrawalDato-DXd EU MAA withdrawn for nonsquamous NSCLC
EU, EMA · Source ↗
22 September 2023Topline resultTROPION-Breast01 topline: PFS met
Daiichi Sankyo · Source ↗
3 July 2023Topline resultTROPION-Lung01 topline: PFS met, OS not significant at interim
Daiichi Sankyo · Source ↗